Plain-English translation of NCT06638944 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new wearable sensor device called i-Phagia that helps people with swallowing difficulties from stroke or Parkinson's disease. The device uses muscle sensors to give you real-time feedback during swallowing exercises, helping you practice more effectively. Researchers want to know if using this device alongside standard swallowing therapy works better than therapy alone, and whether it works equally well when done at home via video visits versus in-person clinic visits.
Swallowing problems are common after stroke and in Parkinson's disease, but treatment options are limited and not always easy to access. This trial aims to fill that gap by testing whether this affordable, wearable feedback device can make swallowing therapy more effective and accessible—especially for people who cannot easily travel to a clinic.
You likely qualify if…
You likely don't qualify if…
You will take part in a 12-week swallowing therapy program with one treatment session per week and 3 days of home practice per week. You will be randomly assigned to one of three groups: using the sensor device in a clinic, using the sensor device at home via telehealth video visits, or doing standard swallowing therapy without the device. You will also come to the clinic for three evaluation visits—one before treatment starts, one after treatment ends, and one 12 weeks later—so the research team can measure how much your swallowing has improved.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
United States